[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Roivant Sciences Ltd (ROIV)

Roivant Sciences Ltd (ROIV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 21,463,872
  • Shares Outstanding, K 715,701
  • Annual Sales, $ 8,260 K
  • Annual Income, $ -299,770 K
  • EBIT $ -1,285 M
  • EBITDA $ -1,282 M
  • 60-Month Beta 1.14
  • Price/Sales 2,589.00
  • Price/Cash Flow N/A
  • Price/Book 4.04

Options Overview Details

View History
  • Implied Volatility 43.67% (+1.74%)
  • Historical Volatility 50.70%
  • IV Percentile 40%
  • IV Rank 27.35%
  • IV High 87.70% on 02/11/26
  • IV Low 27.09% on 06/17/25
  • Expected Move (DTE 17) 2.03 (6.77%)
  • Put/Call Vol Ratio 0.18
  • Today's Volume 368
  • Volume Avg (30-Day) 1,451
  • Put/Call OI Ratio 0.63
  • Today's Open Interest 43,165
  • Open Int (30-Day) 38,269
  • Expected Range 27.96 to 32.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.36
  • Number of Estimates 2
  • High Estimate $-0.30
  • Low Estimate $-0.42
  • Prior Year $-0.30
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.52 +8.98%
on 05/04/26
32.79 -8.55%
on 05/20/26
+2.47 (+8.98%)
since 04/29/26
3-Month
25.95 +15.56%
on 03/30/26
32.79 -8.55%
on 05/20/26
+1.05 (+3.63%)
since 02/27/26
52-Week
10.59 +183.19%
on 05/29/25
32.79 -8.55%
on 05/20/26
+19.37 (+182.39%)
since 05/28/25

Most Recent Stories

More News
Roivant Sciences Q4 Earnings Call Highlights

Roivant Sciences (NASDAQ:ROIV) executives used the company’s fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary...

ROIV : 29.99 (+0.37%)
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant...

ROIVW : 2.75 (-3.85%)
ROIV : 29.99 (+0.37%)
Roivant's Cash Runway Gets Its Clearest Disclosure in a Year

Barchart Research What to Expect from ROIV Earnings ROIV Generated May 19, 2026 Current Price $28.20 EPS Estimate $$-0.38 Consensus Rating Strong Buy Average Move 5.78% Roivant's Cash Runway Gets Its Clearest...

ROIV : 29.99 (+0.37%)
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026

BASEL, Switzerland and LONDON and NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday,...

ROIVW : 2.75 (-3.85%)
ROIV : 29.99 (+0.37%)
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026 

DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq:  IMVT ) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026,...

IMVT : 33.30 (-0.60%)
ROIV : 29.99 (+0.37%)
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved...

ROIVW : 2.75 (-3.85%)
ROIV : 29.99 (+0.37%)
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved...

ROIVW : 2.75 (-3.85%)
ROIV : 29.99 (+0.37%)
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine , underscoring the practice-changing potential of brepocitinib 30 mg once-daily in dermatomyositis Brepocitinib...

ROIVW : 2.75 (-3.85%)
ROIV : 29.99 (+0.37%)
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal If the $1.3 billion payment is realized,...

ABUS : 4.56 (-0.87%)
ROIV : 29.99 (+0.37%)
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna

Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal If the $1.3 billion payment is realized,...

ABUS : 4.56 (-0.87%)
ROIVW : 2.75 (-3.85%)
ROIV : 29.99 (+0.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Roivant Sciences is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences, formerly known as Montes Archimedes Acquisition Corp., is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 31.16
2nd Resistance Point 30.79
1st Resistance Point 30.39
Last Price 29.99
1st Support Level 29.62
2nd Support Level 29.25
3rd Support Level 28.85

See More

52-Week High 32.79
Last Price 29.99
Fibonacci 61.8% 24.31
Fibonacci 50% 21.69
Fibonacci 38.2% 19.07
52-Week Low 10.59

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.